MAP4K3/GLK: Structure, molecular pharmacology and drug development
Bioorganic Chemistry · 2025-10 · 165 · 109043
DOI: 10.1016/j.bioorg.2025.109043 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2025-10. Verfasst von Jingwen Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China; Zhangjiang Institute for Advanced Study, Shanghai JiaoTong …. Hauptthemen laut MEDLINE: Drug Development, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
GLK (also known as MAP4K3), classified as a member of the MAP4K family, is a Ste20-like serine/threonine kinase. GLK plays a pivotal role in multiple cellular signaling pathways, including TCR-mediated immune responses, as well as the JNK, mTOR, and NF-κB signaling pathways. Due to its critical role in these key regulatory networks, GLK has been implicated in the pathogenesis of various diseases, including autoimmune diseases, cancer, aging, and COVID-19 infection. Consequently, GLK represents a promising molecular target for the development of novel therapeutic interventions for immunotherapy and oncotherapy. This review comprehensively summarizes the signaling pathways and human diseases regulated by GLK, focusing on GLK protein kinase structure, GLK-specific regulators, and profiling strategies for developing GLK-specific small-molecule inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China; Zhangjiang Institute for Advanced Study, Shanghai JiaoTong University, Shanghai 201210, China.
- RedCloud Bio Co., Ltd, Beijing 102206, China.
- School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
- Department of Biochemistry and Biophysics, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
- School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China; Zhangjiang Institute for Advanced Study, Shanghai JiaoTong University, Shanghai 201210, China; Institute of Translational Medicin…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Yan, X., Li, H., Shen, Y., Yun, C., & Zhang, J. (2025). MAP4K3/GLK: Structure, molecular pharmacology and drug development. Bioorganic Chemistry, 165, 109043. https://doi.org/10.1016/j.bioorg.2025.109043
Vancouver
Wang J, Yan X, Li H, Shen Y, Yun C, Zhang J. MAP4K3/GLK: Structure, molecular pharmacology and drug development. Bioorganic Chemistry. 2025;165:109043. doi:10.1016/j.bioorg.2025.109043
BibTeX
@article{Wang2025,
author = {Wang, Jingwen and Yan, Xiaoe and Li, Haibo and Shen, Yudao and Yun, Caihong and Zhang, Jianming},
title = {MAP4K3/GLK: Structure, molecular pharmacology and drug development},
journal = {Bioorganic Chemistry},
year = {2025},
volume = {165},
pages = {109043},
doi = {10.1016/j.bioorg.2025.109043}
}
EUVIMED